Sheridan John F 4

4 · TANDEM DIABETES CARE INC · Filed Feb 19, 2026

AI-generated summary of this filing

Updated Feb 19, 2026

Tandem (TNDM) CEO John Sheridan Exercises RSUs; Shares Withheld

What Happened

John F. Sheridan, President & CEO of Tandem Diabetes Care (TNDM), had RSUs convert to common stock on 2026-02-17. The filing shows the conversion/acquisition of 11,454 shares (5,471 + 5,983) from vested RSUs and the company withheld 4,363 shares to satisfy tax withholding obligations at $18.95 per share (total withheld value reported as $37,199 and $45,480, combined ~$82,679). Net shares delivered to Sheridan after withholding: 7,091.

Key Details

Transaction date: 2026-02-17; filing date: 2026-02-19 (filed timely).
Reported entries: M = conversion/exercise of derivative (RSU) into 11,454 shares; F = shares withheld for taxes (4,363 shares) at $18.95.
Cash value of shares withheld: $37,199 (1,963 shares) + $45,480 (2,400 shares) = $82,679.
Shares owned after the transaction: not specified in the Form 4.
Footnotes: F1 notes shares were withheld by the company to satisfy tax withholding (no open‑market sale). F2–F6 describe the awards under the 2023 Long‑Term Incentive Plan and the RSU vesting schedules; F3 notes RSUs may be settled in stock or cash at the company’s discretion.

Context

This was vesting/settlement of RSUs, not an open‑market purchase or sale. The company withheld shares to cover taxes (a routine cashless-withholding settlement), so no shares were sold on the market. The filing uses code M (derivative exercise/convert) for the RSU settlement and code F for tax-withholding.

Form 4

Period: 2026-02-17

DirectorPRESIDENT & CEO

Transactions

Exercise/Conversion
Common Stock
2026-02-17+5,471→ 123,071 total
Tax Payment
Common Stock
[F1]
2026-02-17$18.95/sh−1,963$37,199→ 121,108 total
Exercise/Conversion
Common Stock
2026-02-17+5,983→ 127,091 total
Tax Payment
Common Stock
[F1]
2026-02-17$18.95/sh−2,400$45,480→ 124,691 total
Exercise/Conversion
Restricted Stock Unit
[F2][F3][F4]
2026-02-17−5,471→ 5,472 total
→ Common Stock (5,471 underlying)
Exercise/Conversion
Restricted Stock Unit
[F5][F3][F6]
2026-02-17−5,983→ 29,911 total
→ Common Stock (5,983 underlying)

Footnotes (6)

[F1]Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
[F2]Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
[F3]Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
[F4]RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
[F5]Awarded on May 23, 2024 pursuant to the 2023 Plan, as amended.
[F6]RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Signature

/s/ Shannon M. Hansen, Attorney-in-Fact for John F. Sheridan|2026-02-19

1 file